Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180674 | 0.80 | DGAT1 (0.41) | SYKKCNH2DGAT1 | |
| SCHEMBL182490 | 0.79 | APP (0.51) | ABL1BCRAPPKCNH2DGAT1 | |
| Hydrochloric Acid SCHEMBL181048 | 0.78 | APP (0.50) | ABL1BCRAPPKCNH2DGAT1 | |
| SCHEMBL13646232 | 0.78 | DRD2 (0.47) | DRD2KCNH2 | |
| SCHEMBL27758112 | 0.77 | FPR2 (0.37) | SYKDGAT1 | |
| SCHEMBL181163 | 0.76 | ABL1 (0.37) | SYKABL1BCRDGAT1 | |
| SCHEMBL27758110 | 0.76 | AR (0.38) | ABL1BCRDRD2DGAT1 | |
| Tert-Butyl Formate SCHEMBL27758111 | 0.71 | DGAT1 (0.45) | APPKCNH2DGAT1 | |
| SCHEMBL180746 | 0.69 | DGAT1 (0.56) | SYKABL1BCRDGAT1 | |
| SCHEMBL13664068 | 0.68 | DGAT1 (0.35) | SYKABL1BCRDGAT1MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8835451-B2 | Compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| CN-103288721-A | (4-(4-[6-(trifluoromethyl-pyridin-3-ylamino)-n-containing-heteroaryl]-phenyl)-cyclohexyl)-acetic acid derivatives and pharmaceutical uses thereof | NOVARTIS AG | 2013-09-11 | — | — | CN | disclosed |
| CN-101415683-B | Novel compounds | NOVARTIS AG | 2013-07-17 | — | — | CN | disclosed |
| CN-103086981-A | New compounds | NOVARTIS AG | 2013-05-08 | — | — | CN | disclosed |
| US-20130018074-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018054-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| EP-2418202-A1 | New compounds | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2404905-A1 | New compounds | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2402319-A1 | DGAT Inhibitors | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402318-A1 | DGAT inhibitors | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402317-A1 | DGAT inhibitor | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | disclosed |
| CN-101415683-A | Novel compounds | NOVARTIS AG (CH) | 2009-04-22 | — | — | CN | disclosed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | SYK 4884/4885ABL1 3908/4885BCR 2341/4885 |
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | SYK 4884/4885ABL1 3908/4885BCR 2341/4885 |
| US-20130018054-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | SYK 4884/4885ABL1 3870/4885BCR 2558/4885 |
| US-20130018074-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | SYK 4884/4885ABL1 3870/4885BCR 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.